Introduction
Epilepsy is a chronic neurological condition that places a high economic burden on patients from childhood to senescence. In Hong Kong alone, more than 70 000 patients have seizures as a chronic condition and many more have developed seizures as a result of an acute symptomatic medical condition; both of which may require the use of antiepileptic drugs (AEDs). There are currently 155 registered pharmaceutical products in Hong Kong classed as AEDs and approved by the Department of Health, excluding drugs that are prescribed off-label. The general guiding principles for physicians in the selection of AEDs are derived from evidence-based medicine and the last version of The Hong Kong Epilepsy Guideline already provides ample advice. 1 As the number of published papers and metaanalysis is fast-growing, The Hong Kong Epilepsy Society (HKES) considers it important to review the best available evidence and to update all practising physicians with regard to their position on a range of clinical issues including drug-related matters. As such, HKES prepared a series of consensus statements to supplement The Hong Kong Epilepsy Guideline of 2009.
Four consensus meetings were convened between May 2014 and April 2016 during which time a group of 15 professionals consisting of neurologists, paediatricians, neurosurgeons, radiologists, and clinical psychologists participated in structured discussions in four major areas: AEDs, status epilepticus, refractory epilepsy, and women and epilepsy. The participants represented both the public and private sectors. They were all council members of HKES. The current paper addresses the topic of AEDs.
In part A of this consensus statement, we have compiled all the papers and studies published in 2007 or later, using the citation index from PubMed, Ovid and Google Scholar, that are concerned with the clinical use of AEDs as either monotherapy or adjunctive therapy. The research papers must be written in English with seizure outcome as their primary endpoint. Only AEDs licensed in Hong Kong after 2001 are included in this review. Studies pertaining to benzodiazepine and intravenous preparations only of any AED were not reviewed, nor were those that focused exclusively on subgroups of patients in which prognosis may be affected by parameters other than drug treatment (eg neurosurgical cohorts).
The research papers were rated as randomised controlled trial, cohort study (including retrospective study), meta-analysis or review, and where possible, graded as class I, II, or III level of evidence, in line with the previous version of The Hong Kong Epilepsy Guideline. 1 Level A evidence is defined as the availability of one Class I study or more, or metaanalysis suggesting a similar rating. Level B evidence is defined as the availability of one Class II study or more, or meta-analysis suggesting a similar rating. Level C evidence is defined as the presence of more than two Class III studies.
In part B of this consensus statement, we have compiled all the studies published in 2007 or later, using the citation index from PubMed, Ovid and Google Scholar, that are related to human studies of generic preparations of AEDs. The same classification of evidence is employed. The analyses in both parts A and B are of particular importance to local health care providers, because Hong Kong has a special health-financing situation in which the majority of patients are treated under the public hospital system. As a result, hospital-based practice is likely to influence the standard of care delivered to the majority of chronic epilepsy patients and the health care costs of medical treatment.
Part A: evidence on new antiepileptic drugs
A total of 95 eligible papers were submitted for the purpose of writing this consensus statement. Articles that focused on zonisamide, eslicarbazepine, and brivaracetam were not reviewed because these agents were not registered with Department of Health at the time of writing. Papers pertaining to topiramate were not reviewed as the drug was registered in Hong Kong before 2001. Papers on retigabine were not reviewed as this drug has currently limited usage in Hong Kong following an alert from the Food and Drug Administration (FDA) of the United States. The remaining drugs of interest were collated based on their indications.
Monotherapy

Levetiracetam
Two Class I studies, 10 Class II studies, and 16 Class III studies were found under this indication for levetiracetam (LEV). One Class I study that randomised patients to LEV or carbamazepine found non-inferiority of LEV. 2 Another Class I study randomised paediatric patients with juvenile absence epilepsy to LEV or placebo and reported a nonsignificant superiority in terms of seizure response. 3 One Class II study compared LEV with lamotrigine (LTG) and another Class II study compared LEV with carbamazepine or sodium valproate. Both studies demonstrated that LEV was as efficacious as the other standard regimens. 4, 5 The evidence in the paediatric population was generally positive. 3, 4, 6, 7 At the opposite end of the spectrum, geriatric patients were also shown in a Class II study to benefit from LEV monotherapy. 8 One Class II study detailed the conversion of treatment in patients with existing partial-onset epilepsy to extended-release LEV monotherapy. 9 In the Chinese population, one Class III study demonstrated the usefulness of LEV monotherapy. 10 The overall level of conclusion is supported by an expedited review from the International League Against Epilepsy (ILAE).
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Statement 1: The level of evidence for LEV monotherapy reaches Level A.
Oxcarbazepine
Four Class III studies and one meta-analysis were found under this indication for oxcarbazepine (OXC). Another three Class III studies recruited patients with mixed indications (Table 1 12-19 ). The evidence in the paediatric subgroup suggested that OXC may be useful in children across a range of conditions, from idiopathic to symptomatic and cryptogenic epilepsy. 12 Of interest, one study that recruited Chinese patients for the purpose of both mono-and adjunctive therapy showed that OXC was as effective as LTG or topiramate. 13 Oxcarbazepine is already indicated as monotherapy in partial epilepsy. The recommendation for the use of OXC remains unchanged.
Statement 2: The level of evidence for OXC monotherapy remains unchanged (Level A).
Lacosamide
Lacosamide (LCS) produces slow inactivation of neuronal sodium channels. We found one Class 20 In another study, the seizure-free rate was 72.3% at 1 year and the withdrawal rate was 15%. 21 In the study by Lattanzi et al, 22 58 patients were converted from a background single AED to LCS with just over half (55.2%) becoming seizure-free. Only 20.8% of patients reported mild-to-moderate adverse events. The FDA has approved use of LCS as monotherapy in epilepsy since September 2014 and there was a plan to seek its approval for use with the same indication in Europe in 2016.
Statement 3:
The level of evidence for LCS monotherapy reaches Level B.
Pregabalin
Pregabalin (PGB) has binding properties to the alpha-2-delta units of calcium channels. We found one Class I study, one Class II study, and one metaanalysis for PGB under this indication (Table 3 14, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] ).
Pregabalin was compared with LTG in a study of 330 patients using a double-blind, non-inferiority design with the primary efficacy endpoint being the proportion of patients to achieve seizure freedom for 6 months. In the study, however, PGB was inferior to LTG on both intention-to-treat and perprotocol analyses. 46 In the study by French et al, 14 conversion from a first or second AED to PGB was 
Perampanel
No study on the use of perampanel (PER) monotherapy could be found using the current search criteria. Other information pertaining to PER is shown in Table 4 .
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Statement 5: The level of evidence for PER monotherapy remains unchanged (no recommendation). 
Adjunctive therapy
Levetiracetam
One Class I and two Class III studies were identified using the search criteria. In addition, two Class III studies reported mixed indications and two meta-analyses were published (Table 5 2-10,13,70-94 ). In the only Class I study available for this indication, patients with idiopathic generalised epilepsy were randomised to receive LEV 3000 mg per day or placebo. The results suggested that a reduction by ≥50% of myoclonic seizures may be achieved in 58.3% of patients. 70 One Class III study reported the use of LEV among patients with rolandic epilepsy or variants: a >50% reduction in seizure frequency was achieved by 62.5% of patients. 71 There is no new recommended level of evidence for LEV under this indication.
A review of the behavioural side-effects of LEV revealed possible variation among paediatric and adult subjects. Nervousness, aggression, and hostile behaviour have been reported as putative behavioural adverse events. In paediatric cohorts, the proportion of such adverse events was 20% to 30%. [70] [71] [72] 94 By comparison, the behavioural sideeffects in adults were less prominent.
72-75,94
Statement 6: The level of evidence for LEV adjunctive therapy remains unchanged (Level A).
Oxcarbazepine
One Class I study and three Class III studies (with mixed indications) were identified (Table 1 12-19 ). In the study by the PROSPER Investigators Study Group, adjunctive OXC reduced seizure magnitude by 38.2% to 42.9%. Adverse event rates and safety profiles suggested improved tolerability. 95 Oxcarbazepine is currently licensed for adjunctive therapy in epilepsy and no change to the current recommended level of evidence was made.
Statement 7: The level of evidence for OXC adjunctive therapy remains unchanged (Level A).
Lacosamide
Three pivotal clinical studies outlined the clinical usefulness of LCS in patients with refractory epilepsy: one Phase II and two Phase III studies. 76, 96, 97 These 12-week, randomised, double-blind, placebocontrolled, multicentre trials enrolled subjects with partial-onset seizures with or without secondary generalisation who were not adequately controlled with one to three concomitant AEDs. Study 1 compared doses of LCS 200, 400, and 600 mg/day with placebo. 96 Study 2 compared doses of LCS 400 and 600 mg/day with placebo. 76 Study 3 compared doses of LCS 200 and 400 mg/day with placebo. 97 Following an 8-week phase to establish baseline seizure frequency, subjects were titrated to the randomised dose. During the titration phase in all three trials, treatment was initiated at 100 mg/day (50 mg given twice daily) and increased by weekly increments of 100 mg/day to the target dose. The titration phase lasted 6 weeks in Study 1 and Study 2 and 4 weeks in Study 3. In all three trials, the titration phase was followed by a maintenance phase for 12 weeks. The primary endpoint was reduction in 28-day seizure frequency (baseline to maintenance phase) compared with the placebo group. A statistically significant effect was observed with LCS treatment at doses of 200 mg/day (Study 3), 400 mg/day (Study 1, 2, and 3) , and 600 mg/day (Study 1 and 2 ).
An observational phase IV open-label study to assess the efficacy, safety, tolerability, and additional outcomes of LCS in Hong Kong patients aged ≥18 years showed that LCS had efficacy and adverse effects similar to those described in the literature from other parts of the world. In a cohort of 105 patients, the proportion who achieved a 50% reduction in seizure frequency was 54.5 with a mean titration time of 6.75 weeks and a mean maintenance dose of 158.6 mg/day. The efficacy profile was satisfactory whether or not LCS was combined with concomitant sodium channel blockers (45.8% vs 46.5%). The side-effect profile included apprehension and aggression, drowsiness and tiredness, headache, memory problems, dizziness, numbness, and gait disturbance (local data).
Statement 8: The level of evidence for LCS as adjunctive therapy reaches Level A.
Pregabalin
Three Class I studies, four Class III studies, and four meta-analyses were found pertaining to PGB under this indication (Table 3 14,46-57 ). One study evaluated the efficacy and tolerability of adjunctive PGB as a controlled-release formulation. The 50% responder rate (ie percentage of patients achieving 50% reduction in seizure frequency) was 45.9% for a daily dose of 330 mg. 98 Another randomised study tested PGB versus LEV in a head-to-head comparison in 409 patients. The drug PGB was non-inferior to LEV with a similar tolerability to LEV as adjunctive therapy. 47 In a multicentre, randomised study of PGB versus placebo, PGB was effective and tolerable as adjunctive therapy in the Asian population. 48 This drug is currently licensed for adjunctive therapy in epilepsy and there is no change to the level of evidence regarding its recommended use.
Statement 9: The level of evidence for PGB as adjunctive therapy remains unchanged (Level A).
Perampanel
A total of four Class I clinical studies demonstrated the efficacy of PER among patients with refractory epilepsy. [58] [59] [60] [61] These were all double-blind studies and all evaluated the 50% responder rate as a seizure 
Part B: Generic drugs
The last version of the The Hong Kong Epilepsy Guideline gave advice on the use of generic drugs, details of which can be revisited in the original guideline of 2009. 1 There might be a perceived difference between pharmaceutical equivalence, which is the requirement of the exact product, and bioequivalence, which is the concept of assigning no difference among products in terms of drug absorption. There have been positional statements that outline the possible risks involved when switching antiepileptic agents from a brand to a generic preparation. 99 Clinicians are understandably perturbed by the prospect of inadvertent seizures and loss of quality of life for their patients. The criteria applied by authorities to license generic products give rise to various issues. For instance, the concept of bioequivalence does not require the generic product to demonstrate clinical efficacy among patients. Most bioequivalence studies are performed among healthy subjects rather than individual patients. Antiepileptic drugs are placed in the same category as immunosuppressants and psychotropic drugs, in which generic substitution is necessarily given consideration before implementation. The benefit of generic AEDs is clear in countries where health care financing is either state-run or public-funded, but may still be important in terms of patient choice in countries where private health care or an insurancebased system is practised because patients may want to lower their premium by using generic products. It may be argued that the use of generic products will increase the potential availability of drugs to a broader population of patients including those who are underprivileged or resident in communities where the drug budget is restricted.
There is a growing need for review and update of recommended guidelines on issues related to generic products as the evidence for newer drugs has become more eminent. The prescription of and expenditure on newer agents has risen sharply over the last 5 to 10 years. Clinicians now have a far greater number of AEDs at their disposal compared with a decade ago. There is divided opinion in the professional community about the use of generic products and when it will be considered optimal and safe for epilepsy patients. In general, communities that rely on a state-financed or government-funded health care system are under greater pressure to consider generic product prescription, compared with private-funded or out-of-pocket payment health care financing systems.
Our literature search identified 13 studies published in or after 2007 that fulfilled the initial inclusion criteria. Four studies were of the Class I category, one of the Class II category, and eight of the Class III category (Table 6 100-116 ). Six studies had LTG as the study AED. [100] [101] [102] [103] [104] [105] Two studies had topiramate as the study focus 106, 115 and the remaining studies adopted multiple drug regimens. [107] [108] [109] [110] [111] A good level of evidence came from a randomised controlled trial of 'generic-brittle' patients in a double-blind, multiple-dose, steady-state, fully replicated crossover bioequivalence study of LTG. The study demonstrated that the generic product was bioequivalent to the brand medication. Such observations were supported by the secondary outcomes of seizure control and tolerability-32 of 35 patients reported no deterioration of seizures, and dose-related adverse events were experienced by 14 patients while on the generic product and 15 patients while on the brand product. The study highlighted the use of the therapeutic level as a guide over a period of time while the patient is switched from brand to generic or vice versa. 100 Two Class I studies with preliminary results disseminated during the annual meeting of the American Epilepsy Society in 2015 showed no deviation from FDA's bioequivalence standards in C max and area under the curve when comparing two most disparate generic products in a single dose and chronic disease model respectively (methodology given in Diaz et al in 2013 101 ). One well-designed study of 35 patients randomised patients from six epilepsy centres to receive LTG as one of two treatment sequences that comprised four study periods of 14 days each, during which time balanced doses of an oral generic LTG product were given every 12 hours. Disparate generic LTG in patients with epilepsy demonstrated bioequivalence with no detectable difference in clinical effects. 102 A similar result was found from the only Class II study from our literature search. 103 The best level of evidence in epilepsy patients supported the switch of LTG (sodium channel blocker) from brand to generic preparation. It remains controversial whether these findings can be extrapolated to other AEDs because LTG is by far one of the most widely used first-line AEDs.
Most Class III studies indicated an opposite result compared with the Class I and II studies. These studies showed that generic substitution may result in increased acute seizure-related events and higher use of medical services. The switch-back rates for AEDs from generic to brand were higher in these studies. Of note, these studies had larger sample sizes but all the studies were retrospective in nature. These studies might also have involved a wide range of prescribing practices and some patient factors might not have been taken into account.
Overall, most studies suggested bioequivalence of brand and generic AEDs. This result was also in keeping with a meta-analysis which concluded that if only the highest level of evidence is considered, there is no significant difference in terms of seizure control, whether or not the patient is taking brand or generic products. 117 A UK pharmacovigilance body, the Medicine and Healthcare products Regulatory Agency, issued guidelines regarding the use of generic products in 2013 and specifically divided AEDs into three categories, each of which had specific recommendations regarding the switching of brand to generic products (Appendix).
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Category 1 relates to products among which a specific manufacturer's product should be ensured (eg phenytoin, carbamazepine, phenobarbital, and primidone). Category 2 relates to products for which generic switching is considered neutral, but clinical judgement should be exercised in so doing 119 recommended that a consistent supply should be made available to the epilepsy patient unless the prescriber, in consultation with the patient, considers that this is not a concern.
We acknowledge the controversy about switching from a brand to a generic product. There appears to be a divide in the positional statements and guidelines between countries with public-funded health care and those with private health care. Many associations, including the Italian League Against Epilepsy, 112 American Academy of Neurology, 114 and the French Chapter of ILAE 113 have expressed concerns about generic substitution of AEDs, emphasising the uniqueness of epilepsy as a class of disease in which generic substitution is problematic when carried out for this indication. The latest position statement from the American Epilepsy Society acknowledges the bioequivalence of brand and FDA-approved generic products and the fact that substitution may reduce cost without compromising efficacy. The Society advises the importance of using either immediate-release or extended-release preparations uniformly throughout the switching process. They acknowledge that tablet or capsule colour or shape may impact drug compliance. They also state that the counselling of switching should include an indication of bioequivalence and not inferiority when the information is conveyed to the patient(s) and their family members. 114 A pilot study pioneered by the Hospital Authority Head Office on the switching of phenytoin from a generic back to a brand product due to supplier issues suggested that proper counselling and followup logistics in conjunction with a pre-and post-drug level at 2 weeks may be adequate for the exercise. In 40 patients recruited from the Prince of Wales Hospital and Queen Mary Hospital, no patients developed a toxic level of plasma phenytoin during the switching process (four patients had a toxiclevel pre-switching that remained post-switching). Plasma phenytoin concentration increased in 23 patients and decreased in 17. The conclusion was that there was no consistent trend in the change of plasma drug level (personal communication). Apart from isolated cases of reported dizziness, no serious adverse event occurred. The rate of hospitalisation as a result of the switch in that study was not available to us at the time of writing this review.
Statement 11: There is Level A evidence for generic substitution of LTG (a sodium channel blocker), taking into account the drug's pharmacodynamics and pharmacokinetics.
The HKES upholds the safety of patients above all else. Following a review of the current evidence, the HKES has made the following revisions for the reference of physicians. Doctors can initiate treatment in patients with epilepsy with either a brand or generic product. Switching from a brand to a generic product or between generic products requires great care by clinicians and health care administrators. Automatic substitution at a pharmacy level is not recommended. If switching takes place as a result of cost considerations, prescriber and patient approval must be sought, in liaison with the pharmacist. Prescriber approval is not equivalent to a medical decision. The course of treatment, including choice of drug and dosage, is determined by the doctor and forms part of a medical decision. When the use of generic drugs is based on cost-effective analyses, prescriber approval is a logistic and economic decision. Depending on the type of health care setting, a request for generic substitution may begin with the patient or the health administrator, in liaison with the attending doctor/ pharmacist. Patient approval may not be equivalent to medical consent. This can be a requirement of the health care system to which the patient belongs or a self-initiated step from the patient who has subscribed to insurance plans with affordable premiums. The physician should discuss any switch with the patient from both a medical and layman's perspective. Good communication is considered fundamental to the provision of care. 120 Therefore, in a private health care system, the choice for generic drugs may begin with a patient's request, followed by prescriber approval. In a public health care system, the choice for generic drugs may begin with prescriber's request, followed by patient approval. Follow-up and monitoring logistics should be mutually agreed to ensure patient safety. A change in the physical appearance of medications may hinder compliance. This facet of the switch must be taken into account by all parties. In the special situation where switching from a brand to a generic product takes place among patients who have achieved remission while on antiepileptic therapy, clinicians must take into account the drug's pharmacokinetics and the support of medical services. Assistance from nursing staff, enlisting therapeutic blood monitoring, and the option to use the AED as a self-financed item (both public and private setting) should be made available.
Statement 12: Controversy exists over the use of generic products among patients who are currently taking brand medications. Prescriber and patient approval is pivotal. There should be good communication between doctors and patients; enlisting assistance from doctors, nurses, and pharmacists; therapeutic blood monitoring if available; and the option of brand AED as a selffinanced item. The physical appearance of generic drugs may hamper drug compliance. Support from medical services is recommended. In the longer term, the benefit of flexibility and the option to have balanced use of generic and brand drugs may need to be addressed by institutions and regulatory bodies.
Conclusions
New evidence on AEDs has arisen since the publication of the Hong Kong Epilepsy Guideline in 2009. There is Level A evidence for LEV monotherapy and Level B evidence for LCS monotherapy. There is Level A evidence for LCS and PER adjunctive therapy. No change to the level of evidence is evident for LEV, OXC, and PGB. The use of generic preparations of AEDs should be considered following prescriber and patient approval, with support from medical services (doctors, nurses, pharmacists). It is important to emphasise that a generic preparation is not inferior, that shape and colour of tablets may be different, there may be therapeutic blood monitoring (if available), and patients may have the option of selffinancing items.
